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ABSTRACT 
 Adherence to antiretroviral therapy is a major determinant of successful 
management of HIV. Poor adherence is associated with development of viral resistance, 
virologic failure, and progressive immunosuppression. This project looked at an 
association between poor adherence and distance that patients travel to receive ART. 
HIV infected patients between 18 and 89 years old receiving ART at 7 health facilities in 
Mbeya City, Tanzania were included in the study; pregnant women were excluded. 
Generalized Linear Regression and Zero Inflated Poisson models were used for analysis 
with age, sex, marital status, WHO HIV stage at ART initiation, and number of visits 
adjusted. Results for the primary analysis showed, on average the risk of poor 
adherence reduces by approximately 14.8% for every one mile increase in travel 
distance to an ART facility (95% CI: 6.8-21.3, p=0.0002). The risk of poor adherence is 
20.9% lower for patients younger than 50 years compared to those that are 50 years and 
older (95% CI: 5.1-40.5, p=0.007), married patients have 55.3% higher risk of poor 
adherence compared to unmarried patients (95% CI: 3.05-131.6, p=0.034), and patients 
with WHO HIV stage 1 or 2 at ART initiation have a 22.1% higher risk of poor adherence 
compared to patients with WHO HIV stage 3 and 4 at ART initiation (95% CI: 0.0-49.18, 
p=0.05). 
 The form and content of this abstract are approved. I recommend its publication.  
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Acquired Immunodeficiency Syndrome (AIDS) remains one of the world’s most 
serious health challenges. Countries in the Sub-Saharan region, including Tanzania, are 
severely affected with nearly 1 in 20 adults living with Human Immunodeficiency Virus 
(HIV). This accounts for 71% of people living with HIV globally (WHO 2015). In 2013, the 
total number of people living with HIV in the world was estimated to be 35.0 million; in 
2012 an estimated 2.3 million people were newly infected, and deaths caused by AIDS 
were estimated to be 1.6 million (UNAIDS 2013, WHO 2015).  
By the end of 2013, an estimated 1.4 million Tanzanians were living with HIV and 
approximately 79,000 were newly infected, with about 78,000 lives lost to HIV/AIDS 
related illnesses (UNAIDS 2013, UNAIDS 2014). This loss has negative personal and 
socio-economic implications on families, communities, and a nation as a whole. In the 
effort to fight HIV/AIDS, Tanzania’s Ministry of Health and Social Welfare in collaboration 
with international partners and donors has implemented prevention, care, and treatment 
policies to lower the disease burden. These efforts enabled 384,816 new HIV infected 
patients to have access to Antiretroviral Therapy (ART) by the end of 2010, 626,444 new 
patients by the end of 2011, and 512,555 new patients by the end of 2013 (MoHSW 
2011, TACAIDS 2012, UNAIDS 2014).  
1.1 Antiretroviral Therapy  
ART with its variation in regimens has been proven to effectively manage 
HIV/AIDS (Holtzer C. et al. 1999, AIDSInfo 2015). The therapy helps to reduce HIV/AIDS 
related morbidity and mortality; it inhibits HIV replication so that HIV RNA (viral load) 





2001, Buzon M. J. et al. 2014, AIDSInfo 2015). This can be achieved when the therapy 
is used in a nearly perfect manner, but this does not come without side effects and 
adherence challenges (Chen W. T. et al. 2013, Tadesse W. T. et al. 2014). Alternatively, 
management of HIV/AIDS without treatment leads to development of progressive 
immunosuppression, leading to AIDS defining illnesses and premature death (Deeks S. 
G. et al. 2001, Barron Y. et al. 2004, AIDSInfo 2015).  
1.1.1 Monitoring Adherence to ART 
Adherence to ART is one of the major determinants of successful treatment 
outcomes among HIV-infected individuals (Bangasberg et al. 2001, De Olalla et al. 
2002). Poor adherence, especially at levels less 95% is associated with development of 
viral resistance, virologic failure, disease progression, and eventually death (Lima V. et 
al. 2008, Petrella M. et al. 2001, Bangsberg D. R. et al. 2001, Ekstrand M. L. et al. 2011, 
Henegar C. E. et al. 2014).  
There are several ways of monitoring adherence to ART with no gold standard. 
Information can be obtained by asking patients to self-report the type and number of pills 
or doses missed. Providers can also assess adherence by counting the number of 
remaining pills during patients’ clinic appointments (Thirumurthy H. et al. 2012, Kelly J. 
D. et al. 2013). Pharmacy records are also used to monitor adherence by calculating 
medication possession ratio that assesses drug refill adherence (Cocohoba J. M. et al. 
2003, Sattler E. L. et al. 2013). There are more sophisticated ways of assessing 
adherence that may not be easily accessible in resource limited areas. Electronic 
monitoring devices such as pill bottles are used to record each time a bottle is opened 
and later provide data that show patients’ adherence patterns (Haberer J. E. et al. 2013, 
Vreeman R. C. et al. 2014). Adherence can also be determined by measuring drug 





of drugs (Morey T. E. et al. 2013, Castillo-Mancilla J. R. et al. 2014, Olds P. K. et el. 
2015). Any combination of these methods may be used and the choice depends on the 
ability to effectively implement the methods at a cost that a treatment facility is willing 
and able to incur.  
1.1.2 Adherence Challenges in Resource Limited Settings 
Regardless of the proven benefits of ART in improving health and quality of life, 
there are several challenges that hinder patients in resource limited settings from 
attaining full benefit from the therapy. Wakibi S. N. et al. 2011 conducted a survey in 3 
ART clinics in Kenya. 403 patients between 18 and 64 years old were interviewed. 80% 
of respondents had been receiving ART for at least a year. Using self-reports, 18% of 
patients had less than 95% adherence with forgetfulness accounting for 38% of reasons 
for poor adherence. Patients with access to ART clinics within walking distance from 
their homes were 2.39 times more likely to have poor adherence that patients that 
travelled far for ART (OR=2.39, 95% CI: 1.16 - 4.93), also difficulty with regimen 
schedule (OR=2.31, 95% CI: 1.21- 4.41) predicted non-adherence. Adeneye A. K. et al. 
2006 through a questionnaire reported 25.6% of 125 patients in Nigeria were not willing 
to seek ART from nearest facilities due to stigmatization. However, Sasaki Y. et al. 2012 
interviewed 157 patients in Zambia between 18 and 64 years old at ART initiation and 
after six weeks with 53.8% of patients reporting poor adherence due to long travel 
distance to ART facilities. Food insufficiency (51.3%) and being preoccupied with various 
activities (38.5%) also attributed to poor adherence.  
Watt H. et al. 2013 surveyed 340 patients in Tanzania that had been taking ART 
for an average of 14 months. 5.9% of the patients reported less than 95% adherence. 
Patients reported forgetting (45%), travelling (20%), untimely drug refills (9%), illness or 





al. 2012 interviewed 61 patients from four different ART clinics in Tanzania. Because of 
stigma and HIV positive status disclosure concerns, 23% of patients avoid receiving ART 
at nearby clinics instead chose to go further from their homes. Mbonye M. et al. 2013 
conducted an extensive adherence survey of 24 patients that were followed for 6 years 
in Uganda with 25% of patients challenged by continuing side effects that affected their 
appearance such as lipodystrophy. 
1.2 Application of Geographic Information Systems 
Health data can be linked to point data (ZIP code, ward, county, state, or country) 
to describe presence or absence of diseases, disease outbreaks, and disease trends. 
These can further be described by population density, socio-economic and 
environmental factors, and other factors that can be linked to a location. Variations in the 
spread of diseases, disease management, survival rates, and vaccine efficacy can also 
be explained in depth by utilizing Geographic Information Systems (GIS). The 
application of GIS helps to analyze and visualize the effects, association, and variation 
of factors by geographical location (Gatrell A. C. et al. 1996, Berke E. M. at al. 2010, 
Root E. D. et al. 2014). 
GIS has useful application in the field of medicine. Erickson S. R. et al. 2014 
conducted a geospatial analysis of statin adherence in Michigan. They used medication 
possession ratios to determine medication adherence of 212,783 adult patients. Clusters 
with high and low adherence levels were obtained by hotspot analysis and presented on 
maps by ZIP code. The study found clusters of ZIP codes with different adherence 
levels. The mean medication possession ratio (MPR) was 0.79 (95% CI: 0.01-1.57). The 
mean for higher adherence ZIP codes was 0.83 (95% CI: 0.77-0.89) and for lower 
adherence was 0.76 (95% CI: 0.70-0.82). Hoang C. et al. 2011 conducted a study to 





drug adherence. The study assessed the adherence of 1,081 adult patients who had 
been prescribed continuing treatment, 6 to 12 months after hospital discharge for acute 
coronary syndrome in southeast Michigan. Using Hot Spot Analysis, they identified 
geographic areas of high, low, and neutral adherence rates and presented results on 
maps.  
Shacham E. et al. 2013 conducted a study in the St. Louis metropolitan area to 
assess an association between neighborhood conditions and management of HIV and 
engagement in high-risk behaviors. 762 patients in 273 census tracts were part of this 
study, 74% were receiving ART. Their results showed patients that live in areas with 
higher poverty rates were more likely to have CD4+ T cell counts less than 200 cells/μL 
(OR=1.56, 95% CI: 1.05-2.44). Areas with higher unemployment rates were less likely to 
have current ART prescriptions (OR=1.47, 95% CI: 1.05-2.04). Another study by 
Eberhart M. G. et al. 2013 looked at spatial analysis of patterns along the HIV care 
continuum in Philadelphia. The study identified 1,704 people who were newly diagnosed 
with HIV from an HIV/AIDS reporting system in 2008-2009.They identified census tracks 
where patients were not linked to HIV care (OR=1.76, 95% CI:1.30-2.40), not linked to 
care within 90 days (OR=1.49, 95% CI:1.12-1.99), and did not achieve viral suppression 
(OR=3.23, 95% CI: 1.87-5.59).  
A study by Feldacker C. et al. 2010 explored an association between individual 
level risks and individual HIV status in Malawi. The study had 3,918 participants between 
15 and 54 years old. They found that the odds of HIV infection decreased with an 
increase in distance from patients’ residences to health clinics, for men and women 
respectively (OR=0.93, p<0.05 and OR=0.94, p<0.01). They used maps to display 
locations where distance to health clinics, major roads, and majors cities are significantly 





1.3 Use of Electronic Medical Records  
 The use of electronic medical records (EMRs) for research is convenient and 
reduces the cost of data collection. In most cases, data is collected over a long period of 
time providing an opportunity for comprehensive analysis and reliable inferences. 
McDonald E. et al. 2010 utilized EMRs collected over 7 years to compare the 
investigation and management of patients presenting with immune 
thrombocytopenia between their facility and international standards. They analyzed 
records of 67 adult patients in New Zealand. One of this study’s findings was that HIV 
testing was not considered as necessary for this group of patients. 15 of 67 patients 
were tested for HIV and all were HIV negative; 1 of 51 patients not tested was later 
found to be HIV positive.  
 Oluoch T. et al. 2014 evaluated the effect of the change from a paper based 
system to an EMR system on appropriate ART initiation at 17 HIV care clinics in rural 
Kenya. They analyzed records of 18,523 pre-ART patients who were aged 2 years and 
older. This study showed the use of EMRs can improve quality of HIV care in resource 
limited settings. The median time from enrollment into care to first CD4+ T cell count test 
was 0.93 months (IQR: 0.43-3.37) for EMRs compared to 1.4 months (IQR: 0.47-4.87) 
for paper records. The odds of performing baseline CD4+ T cell count tests were higher 
for EMRs compared to paper records (OR=1.57, 95% CI: 1.49-1.66). 25.7% of patients 
with paper records had a follow-up CD4 test at 6 months (95% CI: 24.0-27.5) compared 
to 35.0% of patients with EMRs (95% CI: 31.2-39.1). The hazard ratio of conducting a 
second CD4+ T cell count test for the two systems was higher for EMRs compared to 






There is limited literature that models geographic variation in adherence to ART 
and treatment outcomes. Studies mentioned in section 1.2 (Feldacker C. et al. 2010, 
Hoang C. et al. 2011, Eberhart M. G. et al. 2013, Shacham E. et al. 2013, and Erickson 
S. R. et al. 2014) have shown that geographical location plays a role in patients’ 
adherence to therapy and treatment outcomes. Variation in patients’ access to ART may 
have significant impact on adherence and treatment outcomes.   
1.5 Objectives 
The objectives of this study were to find out if distance from patients’ residential 
wards to ART clinics estimated by shortest distance travelled has any effect on patients’ 
adherence to ART and if there is any geographical variation in patients’ adherence to 
ART. We hypothesized that an increase in distance travelled increases the risk of poor 
adherence.  The significance of understanding geographic variation in patients’ 
adherence to this therapy can help to identify geographical areas that are not receiving 
maximum benefit from care. Identification of these areas will assist policy makers in 









2.1 Data Sources 
This study was conducted in Mbeya, a city located in the Southwest of Tanzania. 
Its land size is 214 square kilometers and has 36 wards. In 2012, this city had an 
estimated total population of 385,279 with 91,733 households and an average 
household size of 4.2 (Mbeya City Council, 2014). Mbeya is one of the regions in 
Tanzania with a high HIV prevalence. In 2012, its prevalence rate was 9.0%, above the 
national average of 5.1% (Tanzania Prime Minister’s Office, 2013). We collected 
demographic, clinical, and geographic data on patients receiving ART, this is further 
described in sections 2.1.1 and 2.1.2.  
2.1.1 Patient Data 
In Tanzania, health facilities that provide ART use a database called CTC2 to 
collect, manage, and store patients’ HIV/AIDS related care and treatment information. 
This database is currently being used by more than 300 health facilities as a stand-alone 
database and is available in every region of the country. It is based on nationally 
standardized paper based HIV care and treatment tools. The database has automated 
features for producing data for analysis and facility level, regional, and national reports 
on HIV/AIDS care and treatment (NACP 2014).  
We utilized a report from stand-alone CTC2 databases to collect demographic, 
clinical, and ward level residential location of patients from all government sponsored 
health facilities that provide ART in Mbeya namely: Mbeya Referral Hospital, Mbeya 





Center, Uhai Baptist Health Center, Igawilo Health Center, and Ruanda Health Center. 
The format of the data we collected is shown on appendix B. 
We included male and female patients between the age of 18 and 89 receiving 
ART at the above mentioned facilities. Pregnant women were excluded from this study 
due to the complexity that this special population could have added to our analyses and 
we would have required additional ethical approvals. ART adherence data we collected 
from EMRs was categorized as good or poor, with patients that missed fewer than 2 
days’ worth of pills in a month as good and those that missed 2 or more days’ worth of 
pills in a month as poor.   
2.1.2 Geographic Data 
 We collected two kinds of geographical data. We used a Global Positioning 
System (GPS) device (Garmin GPSMap 60CSx) to collect longitude and latitude 
coordinates of ART health facilities that were included in the study, as seen on appendix 
C. We obtained geographical location of wards from the 2012 Census shapefile provided 
by Tanzania Bureau of Statistics. 
2.2 Data Cleaning and Management 
 We used SAS software (version 9.3, SAS Institute Inc., Cary, NC) to perform 
data cleaning and management. We interpreted CD4 laboratory values that were above 
1,392 cells per cubic millimeter as outliers or data entry errors. We set these values to 
1,392 cells per cubic millimeter, to conform to the 97.5 percentile of normal laboratory 
ranges in Mbeya, Tanzania (Saathoff E. et al. 2008). We also checked for duplicate 
patient identifiers across facilities and excluded patients that received care from more 





2.3 Data Analysis 
2.3.1 Statistical Methods 
 Table 1 below presents preliminary analysis results that we used to decide on 
how to analyze the data. The table presents the distribution of non-adherence counts 
with 97.7% of the study population having 5 or less counts of poor adherence. With this 
distribution, we chose to use adherence to ART as a binary outcome for our primary 
analysis and per patient poor adherence counts as an outcome for our secondary 
analysis.   
Table 1: Distribution of Non Adherent Counts 
Counts Frequency Percent 
Cumulative 
Percent 
1 488 79.09 79.09 
2 74 11.99 91.09 
3 25 4.05 95.14 
4 8 1.30 96.43 
5 8 1.30 97.73 
6 4 0.65 98.38 
7 2 0.32 98.70 
8 4 0.65 99.35 
9 2 0.32 99.68 
13 1 0.16 99.84 
16 1 0.16 100.00 
Characteristics were summarized with mean and standard deviation, mean and 
95% CI, geometric mean and 95% CI, and median and range for continuous measures; 





normality as appropriate. Summary statistics were compared using t-test for continuous 
and chi-square for categorical measures. In order to analyze the relationship between 
distance and adherence to ART, we fit Generalized Estimating Equations (GEE) with 
random statements as primary analysis, used relative risk of poor adherence as an 
outcome. We also used nonlinear mixed models to fit a Zero Inflated Poisson (ZIP) 
model for secondary analysis with proportion of non-adherent visits as an outcome (SAS 
GEE, NLMIXED online documentation, 2015). Crude and adjusted GEE, adjusted ZIP 
results were reported as relative risk with 95% CI. We adjusted for age, sex, marital 
status, WHO HIV stage, and the logarithm of number of visits as an offset. We used SAS 
software (version 9.3, SAS Institute Inc., Cary, NC) for analyses. All tests were two-sided 
and p<0.05 was considered significant. 
2.3.2 Spatial Methods 
We used Spatial Scan Statistics (SaTScan, version 9.3) with a Bernoulli 
probability model to scan for potential clusters of high and low rates of poor adherence 
(Kulldorff M. 1997). Patients with poor adherence were included as cases and those with 
good adherence as controls as required under the Bernoulli distribution. Latitude and 
longitude coordinates were imported into SaTScan for identification of clusters and 
geographic visualization of results using ArcGIS.  
Spatial scan statistics are a cluster detection method able to find locations of 
significantly high or low clusters within the study region in circular windows of various 
sizes.  At each location, the rate of poor adherence inside the window is compared with 
that outside the window. Under the Bernoulli assumption, the likelihood function for a 


























where C is the total number of cases, c is an observed number of cases, n is the total 
number of cases and controls within a window, N is the combined total number of cases 
and controls provided in the data set, and I( ) is equal to 1 when the window has more 
cases of poor adherence than expected under the null-hypothesis, and 0 otherwise 
(Kulldorff M. 2009). For each window, a likelihood ratio is computed for the alternative 
hypothesis that there is an increased or reduced risk of poor adherent patients inside the 
window, against the null hypothesis that the risk inside the window is the same as that 
outside. A maximal cluster size of 50% of the total study population was used as a 
default recommended option by SaTScan (Kulldorff M. 2015).  SaTScan detects a 
cluster if a window has a disproportionate low or high poor adherent cases compared 
with bordering areas in the study region. Sets of potential clusters are then ranked 
according to the magnitude of their likelihood ratio test statistics. Once the null 
hypothesis is rejected, clusters are formed presenting study areas with significantly high 
or low cases of poor adherence. The p-value is then obtained through Monte Carlo 
simulations (Dwass M. 1957) and are used to assess whether poor adherence rates are 
randomly distributed in space or not (Cuadros D. F. et al. 2013). P-values less than 0.05 
were considered significant. 
2.4 Ethical Considerations 
We obtained ethical approvals from Colorado Multiple Institutional Review Board, 
National Health Research Ethics Review Committee in Tanzania, and from Mbeya 







3.1 Characteristics of the Study Population 
 Demographic and clinical characteristics of the study population are presented in 
Table 2. There were 13,075 patients from 7 health facilities, 2 hospitals and 5 health 
centers. In total, hospitals had more patients than health centers, 7,153 verses 5,922.  
There was a significant difference in the mean age of patients seen at hospitals 
(41.1±10.6) compared to those seen at health centers (37.7±9.9), p<0.0001. The 
average number of ART visits were significantly higher for hospitals (12.7±3.7) 
compared to health centers (7.6±3.1), p<0.0001. Hospitals had a significantly higher 
average distance travelled in miles (1.9±1.6) compared to health centers 
(1.4±1.7), p<0.0001. Also, hospitals had a significantly higher percentage of male 
patients (61.1) compared to health centers (38.9), p<0.001. Alternatively, health centers 
had a significantly higher percentage of married patients (61.9) compared to hospitals 
(38.1), p<0.0001; and a higher mean CD4+ T cell count (123.4±3.2) compared to 
hospitals (83.4±3.5), p<0.0001.  
Across all facilities, there was variation in WHO HIV stage; majority of patients 
were in stage 3 at ART initiation as shown on Table 2. There was also variation in the 
percentage of patients with poor adherence as presented in figure 1, with Igawilo health 
center having the highest percentage of patients with good adherence (99.4) and 










































Age: years ‡ 41±10.7 41±10.4 38±9.9 37±9.9 39±9.6 38±10.0 37±10.6 
Gender: Female - %  61.1 61.8 68.3 74.9 63.8 72.0 71.4 
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Figure 1: Distribution of Counts of Poor Adherence by Health Facility. The number 
of poor adherence counts is presented on the x-axis with corresponding percentage on 
the y-axis per health facility. 
 The geographic distribution of patients is shown on figure 2. This map also 
shows the location of health facilities where study patients received ART. There is a 
variation in the distribution of the number of patients across the wards as presented on 
the map. Due to the edge effect, the lowest number of patients is mostly in wards 








         Figure 2: Geographic Distribution of Study Patients. Distribution of study patients per ward  





3.2 The Effect of Distance on Adherence 
3.2.1 Unadjusted Model 
We fit an unadjusted GEE model for poor adherence with distance as the only 
predictor. Results presented on Table 3 show, on average the risk of poor adherence 
reduces by approximately 16% (95% CI: 7-24, p=0.0005) for every one mile increase in 
travel distance to an ART facility. 





Confidence Interval p-value 
Distance (miles) 0.84* 0.76 0.93 0.0005 
      * Result is statistically significant based on p<0.05 
3.2.2 Primary Analysis 
We adjusted for age, sex, marital status, WHO HIV stage at ART initiation, and 
the logarithm of number of visits as an offset. Results are presented on Figure 3 and 
Table 4. This model shows, on average the risk of poor adherence reduces by 
approximately 14.8% (95% CI: 6.8-21.3, p=0.0002) for every one mile increase in travel 
distance to an ART facility. The risk of poor adherence is 20.9% lower for patients 
younger than 50 years compared to those that are 50 years and older (95% CI: 5.1-40.5, 
p=0.007), married patients have 55.3% higher risk of poor adherence compared to 
unmarried patients (95% CI: 3.05-131.6, p=0.034), and patients with WHO HIV stage 1 
or 2 at ART initiation have a 22.1% higher risk of poor adherence compared to patients 








                             Figure 3: Relative Risk Ratios for GEE Model  
                             Results of unadjusted (crude) and adjusted models are presented here. The adjusted model was adjusted  









Confidence Interval p-value 
Distance 
(miles) 
0.85* 0.79 0.93 0.0002 
Age Group 
(<50 vs ≥50) 








1.55* 1.03 2.32 0.0343 
WHO HIV Stage 
(<3 vs ≥3) 
1.22* 1.00 1.49 0.0500 
     * Result is statistically significant based on p<0.05 
3.2.3 Zero Inflated Poisson Model 
Due to high proportion of patients with zero counts of poor adherence, we fit a 
zero inflated Poisson model to test an association between poor adherence counts and 
distance travelled to ART facilities. We adjusted for age, sex, marital status, WHO HIV 
stage at ART initiation, and the logarithm of number of visits as an offset. Results are 
presented on Table 5 and they indicate that on average, the proportion of non-adherent 
visits is approximately 8.6% smaller for one mile increase in distance (95% CI: 2.0-14.8, 
p=0.024). Other significant predictors of poor adherence are: age, sex, and marital 
status where the proportion of non-adherent visits was higher for patients younger than 
50 years compared to those that are 50 years and older by 47.7% (95% CI: 12.7-91.6, 
p=0.014), higher for male patients compared to female patients by 32.3% (95% CI: 7.3-





35.0% (95% CI: 8.3-68.2, p=0.017). Unlike the GEE model with a binary outcome, this 
model was able to detect significant differences between male and female patients, and 
between patients with WHO HIV stage 1 and 2, and those with stage 3 and 4 at ART 
initiation. 









-3.97 0.12 <.0001 -4.28 -3.65 
Distance 
(miles) 
-0.09* 0.03 0.0244 -0.16 -0.02 
Age Group 
(<50 vs ≥50) 








0.30* 0.08 0.0167 0.08 0.52 
WHO HIV 
Stage 
(<3 vs ≥3) 
-0.09 0.08 0.3121 -0.30 0.12 
  * Result is statistically significant based on p<0.05 
3.2.4 Sensitivity Analysis 
We conducted three sensitivity analyses. First, we fit a GEE model with age, sex, 
marital status, WHO HIV stage at ART initiation, and the logarithm of number of visits as 
predictors of poor adherence. Results are presented on Table 6. This model shows on 
average, the risk of poor adherence reduces by approximately 13.2% (95% CI: 6.4-19.4, 
p=0.0002) for every one mile increase in travel distance to an ART facility. Unlike the 





(RR=11.0, 95% CI: 3.2-27.2, p=0.1354). Similar to the GEE model for the primary 
analysis, married patients have 40.5% higher risk of poor adherence compared to 
unmarried patients (95% CI: 4.4-89.0, p=0.0246), and patients with WHO HIV stage 1 or 
2 at ART initiation have a 24.4% higher risk of poor adherence compared to patients with 
WHO HIV stage 3 and 4 at ART initiation (95% CI: 0.8-53.6, p=0.0423). Similarly, the 
risk of poor adherence increase by 103.3% for every one log increase in the number of 
ART visits (95% CI: 70.2-142.8, p<0.0001).  





Confidence Interval p-value 
Distance 
(miles) 
0.87* 0.81 0.94 0.0002 
Age Group 
(<50 vs ≥50) 








1.41* 1.04 1.89 0.0246 
WHO HIV 
Stage 
(<3 vs ≥3) 
1.24* 1.01 1.54 0.0423 
log(Visits) 2.03* 1.70 2.43 <.0001 
 * Result is statistically significant based on p<0.05 
For the second sensitivity model, we excluded Igawilo Health Center. This center 
reported 99.4% good adherence and we speculated that this center could potentially 
skew results. We used a GEE model and adjusted for age, sex, marital status, WHO HIV 
stage at ART initiation, and the logarithm of number of visits as an offset. Results are 





WHO HIV stage is no longer significant (RR=15.0, 95% CI: 0.0-33.6, p=0.0527). This 
model shows on average the risk of poor adherence reduces by approximately 13.9% 
(95% CI: 7.7-19.7, p<0.0001) for every one mile increase in travel distance to an ART 
facility. The risk of poor adherence is 24.6% lower for patients younger than 50 years 
compared to those that are 50 years and older (95% CI: 9.4-43.3, p=0.0014), married 
patients have 71.6% higher risk of poor adherence compared to unmarried patients 
(95% CI: 16.2-156.0, p<0.0068). 





Confidence Interval p-value 
Distance 
(miles) 
0.86* 0.80 0.93 <.0001 
Age Group 
(<50 vs ≥50) 








1.72* 1.16 2.55 0.0068 
WHO HIV 
Stage 
(<3 vs ≥3) 
1.16 1.00 1.34 0.0527 
 * Result is statistically significant based on p<0.05 
Lastly, we fit a GEE model with age, sex, marital status, and WHO HIV stage at 
ART initiation as predictors of poor adherence and included compound symmetry to 
account for within facility patient correlation. Results of this model are presented on 











Confidence Interval p-value 
Distance (miles) 0.97 0.93 1.01 0.1003 
Age Group 
(<50 vs ≥50) 1.11 0.96 1.29 0.1600 
Male vs Female 
1.16 0.88 1.54 0.2973 
Marital status 
(Married vs Other) 1.22 0.97 1.53 0.0886 
WHO HIV Stage 
(<3 vs ≥3) 1.07 0.92 1.24 0.3619 
 * Result is statistically significant based on p<0.05 
3.3 Spatial Variation 
 Spatial analysis results identified 6 clusters with a high rate of poor adherence 
and 9 clusters with low poor adherence rates. The locations of these clusters are 
presented on Figure 4 and clusters with statistically significant results are marked with 
an asterisk on Table 8. The proportion of patients in clusters of statistically significant 
high rates of poor adherence ranged from 6.9% (RR=1.59, p<0.0001) to 7.2% (RR=1.59, 
p=0.042).  Similarly, the proportion of patients in clusters of statistically significant low 
rates of poor adherence were 2.5% (RR=0.46, p<0.0001) and 1.4% (RR=0.28, p=0.003). 
Table 9: Description of Clusters with High and Low Rates of Poor Adherence 









Ratio P value 
1* 6.9 1.59 11.67 <0.0001 1* 2.5 0.46 24.08 <0.0001 
2* 6.5 1.62 7.31 0.0140 2* 3.4 0.59 8.33 0.0037 
3* 5.5 1.61 10.88 0.0003 3 3.9 0.65 3.82 0.1280 
4* 4.4 1.67 7.87 0.0023 
 
5 3.7 1.51 1.17 0.8800 








           Figure 4: Clusters of High and Low Poor Adherence Rates. Geographical localization of clusters with high       
           poor adherence are in red, with low poor adherence in blue, no presence of clusters in white, and areas with an        






 The objective of this study was to evaluate the geographic variation in adherence 
to ART. We were able to show an association between poor adherence and distance 
that patients travel to receive ART using both statistical and spatial analysis methods. 
Unlike studies like Sasaki Y. et al. 2012 that have shown an increase in distance to ART 
centers has a negative effect on patients’ adherence, our results show patients that are 
willing to travel farther for care may have better adherence. Adeneye A. K. et al. 2006 
and Wakibi S. et al. 2011 observed in their studies that some patients choose not to 
receive care from facilities that are close to them for fear of stigmatization.   
Some of the limitations of this study were: unavailability of viral load laboratory 
results. With these results, we would have been able to analyze the effect of distance on 
patients’ clinical outcomes, specifically the effect of ART on suppressing the viral load. 
This study utilized a clinical database that was not intended for research. Limitations due 
to the use of a clinical database include missing and incompletely recorded data, as well 
as a potential over-reporting of adherence.  The later may be in part due to a motivation 
to report positive results (Reynolds L.J. 2014). Due to missing data, patients that did not 
have wards recorded were excluded from the study (n=1034). Since this study 
depended on patients’ geographical locations for cluster analysis and to calculate 
distance travelled, patients without wards were not evaluable but we compared their 
demographic and clinical characteristics to the study patients’ and found that there is no 
difference in age (p=0.105), marital status (p=0.8121), WHO HIV stage at ART initiation 
(p=0.0735), and CD4+ T cell count (p=0.2169). However, there were differences in sex 
(p=0.0295), number of visits (p=0.0270), and adherence rates (p=0.4971). For patients 





cell count. Complete data could have added value to the analysis especially in probing 








 It is interesting that the results of this study are completely different from what we 
hypothesized. Even though only 5% of 13,075 study patients had at least one event of 
poor adherence, we were able to obtain statistically significant results showing that an 
increase in distance to receive care is associated with better adherence to ART. This 
study only covered a relatively small geographical area where the average longest 
distance travelled was 10.3 miles in an urban area. It would be interesting to expand the 
study to a rural setting where patients travel longer distances to seek ART. We would 
also like to further this research by not only expanding the geographical location but also 
compare the results of monitoring adherence to ART through patients self-report and 
results obtained through other monitoring tools such as using pharmacy refill records 
showing pill possession ratios and the use of biochemical assays that can measure the 
presence of drugs in dried blood spots (Cocohoba J. M. et al. 2003, Sattler E. L. et al. 
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Geographical Location of Facilities 
Facility Name Longitude Latitude 
Mbeya Referral Hospital 33.4393056 -8.8894722 
Mbeya Regional Hospital 33.4452778 -8.9145278 
Kiwanja Mpaka Health Center 33.4340278 -8.8916389 
Iyunga Health Center 33.4244722 -8.9366944 
Ruanda Health Center 33.4597778 -8.9093611 
Uhai Health Center 33.4685833 -8.9082222 









/** Reading raw imported data tables into SAS **/ 
 
PROC SQL; 
create view art_gis.NoDups as 
select * 
from rawadherence  
where rawadherence.patientid  
 not in  
  ( 
   select dupsadherence.patientID 
   from dupsadherence 
  )  
order by 1; 
QUIT; 
 
/** Cleaning and formating raw data **/ 
 
DATA art_gis.AdhAnalysis (drop = PatientID); 
set art_gis.NoDups; 
 
 NewPatientID = _n_; 
 
if distance = 0  then newdistance = 0.0015; 
 else newdistance=distance; /*shortest distance within hospital ward*/ 
 
if adherence = "P" then newadherence = 1; 
 else newadherence = 0; 
 
if age <50 then agegroup = 1; 
if age >=50 then agegroup = 0; 
 
if sex ="Male" then newsex = 1;  
 else newsex = 0; 
 
 classmstatus = 2; 
if maritalstatus = "M" then classmstatus = 0; 
if maritalstatus = " " then classmstatus = 1; 
if maritalstatus = "M" then sumstatus = "Married" ; 
 else if  maritalstatus = " " then sumstatus = "Missing"; 
 else sumstatus = "Other"; 
if sumstatus = "Married" then m = 1 ; else m=0;/*marital status dummy */ 
 
if who <3 then newwho = 1; 
if who >=3 then newwho = 0; 
if who = . then who = 0; 
 





logdistance = log(newdistance); 
artyear = year (StartDate); 
 
if PoorCount >0 then adherence = "P"; else adherence = "G"; 
if adherence = "G" then sumadh = 0; 
 else if  adherence = "P" then sumadh = 1; 
 else sumadh = 2; 
 
 CD4 = MinOfResultNumeric; 
if CD4 > 1392 then CD4 = 1392; /*setting values above normal range*/ 
logcd4 = log(cd4); 
 
if facility = "Mbeya Referral Hospital" then facilityid = 1; 
if facility = "Mbeya Regional Hospital" then facilityid = 2; 
if facility = "Igawilo Health Center" then facilityid = 3; 
if facility = "Iyunga Health Center" then facilityid = 4; 
if facility = "Kiwanja Mpaka Health Center" then facilityid = 5; 
if facility = "Ruanda Health Center" then facilityid = 6; 
if facility = "Uhai Baptist Health Center" then facilityid = 7; 
 
if facility = "Mbeya Referral Hospital"  
  OR facility = "Mbeya Regional Hospital"  
  then newfacility = 0; 
  else newfacility = 1; /*hospitals vs health centers*/ 
 
 ward = ward_shehi; 
if ward = "Mbalizi Road" then ward = "Mbalizi RD"; 
 
if ward = "Forest" then wardid = 1 ; 
if ward = "Ghana" then wardid = 2 ; 
if ward = "Iduda" then wardid = 3 ; 
if ward = "Iganjo" then wardid = 4 ; 
if ward = "Iganzo" then wardid = 5 ; 
if ward = "Igawilo" then wardid = 6 ; 
if ward = "Ilemi" then wardid = 7 ; 
if ward = "Ilomba" then wardid = 8 ; 
if ward = "Isanga" then wardid = 9 ; 
if ward = "Isyesye" then wardid = 10 ; 
if ward = "Itagano" then wardid = 11 ; 
if ward = "Itende" then wardid = 12 ; 
if ward = "Itezi" then wardid = 13 ; 
if ward = "Itiji" then wardid = 14 ; 
if ward = "Iwambi" then wardid = 15 ; 
if ward = "Iyela" then wardid = 16 ; 
if ward = "Iyunga" then wardid = 17 ; 
if ward = "Iziwa" then wardid = 18 ; 
if ward = "Kalobe" then wardid = 19 ; 
if ward = "Maanga" then wardid = 20 ; 
if ward = "Mabatini" then wardid = 21 ; 
if ward = "Maendeleo" then wardid = 22 ; 





if ward = "Mbalizi RD" then wardid = 24 ; 
if ward = "Mwakibete" then wardid = 25 ; 
if ward = "Mwansekwa" then wardid = 26 ; 
if ward = "Mwasanga" then wardid = 27 ; 
if ward = "Nonde" then wardid = 28 ; 
if ward = "Nsalaga" then wardid = 29 ; 
if ward = "Nsoho" then wardid = 30 ; 
if ward = "Nzovwe" then wardid = 31 ; 
if ward = "Ruanda" then wardid = 32 ; 
if ward = "Sinde" then wardid = 33 ; 
if ward = "Sisimba" then wardid = 34 ; 
if ward = "Tembela" then wardid = 35 ; 
if ward = "Uyole" then wardid = 36 ; 
 
wardpresent = "YES"; 
 
RUN; 
proc print data = art_gis.AdhAnalysis (obs=10); run; 
 
/** Table 1 **/ 
 




/** Table 2 **/ 
 
*Age; 






PROC FREQ data = art_gis.AdhAnalysis; 




PROC FREQ data = art_gis.AdhAnalysis; 
tables facility * sumstatus; 
RUN; 
 
*WHO disease stage; 
PROC FREQ data = art_gis.AdhAnalysis; 











*Testing for normality; 
PROC UNIVARIATE data = art_gis.AdhAnalysis plots; 




*transform the data for +ve values; 
 data logcd4; 
    set art_gis.AdhAnalysis; 
    if cd4 >0 then logofcd4=log(cd4); 
 run; 
 
*get mean and 95% CI of log values; 
 proc summary data =logcd4 alpha=.05 nway; 
    class facility; 
    var logofcd4; 
    output out =gm mean=mean lclm=lci uclm=uci; 
 run; 
 
*Geometric mean and its CI; 
 data gmderived; 
    set gm; 
    gm=exp(mean); 
    lcgm=exp(lci); 
    ucgm=exp(uci); 
 run; 





IF cd4 = . THEN misscd4 = 0; 
 ELSE misscd4 = 1; 
run; 
proc freq data = misscd4; 









*Number of visits; 
*Testing for normality; 
PROC UNIVARIATE data = art_gis.AdhAnalysis plots; 







*transform the data for +ve values; 
 data logvt; 
    set art_gis.AdhAnalysis; 
    if numvisits >0 then logofvt=log(numvisits); 
 run; 
 
*get mean and 95% CI of log values; 
 proc summary data =logvt alpha=.05 nway; 
    class facility; 
    var logofvt; 
    output out =gm mean=mean lclm=lci uclm=uci; 
 run; 
 
*Geometric mean and its CI; 
 data gmderived; 
    set gm; 
    gm=exp(mean); 
    lcgm=exp(lci); 
    ucgm=exp(uci); 
 run; 




proc freq data = art_gis.AdhAnalysis; 
tables facility * adherence; 
run; 
 
*Year of ART initiation - narrative; 
proc freq data = art_gis.AdhAnalysis; 































proc freq data = art_gis.AdhAnalysis; 
tables newfacility * newsex / chisq; 
run; 
 
proc freq data = art_gis.AdhAnalysis; 
tables newfacility * m / chisq; 
run; 
 
/**FIGURE  1**/ 
 






If Facility = "Mbeya Referral Hospital" then Facility = "Mbeya Referral"; 
If Facility = "Mbeya Regional Hospital" then Facility = "Mbeya Regional"; 
If Facility = "Igawilo Health Center" then Facility = "Igawilo" ; 
If Facility = "Iyunga Health Center" then Facility =  "Iyunga" ; 
If Facility = "Kiwanja Mpaka Health Center" then Facility = "Kiwanja Mpaka" ; 
If Facility = "Ruanda Health Center" then Facility = "Ruanda" ; 
If Facility = "Uhai Baptist Health Center" then Facility = "Uhai Baptist"; 
Run; 
 
title "Distribution of Poor Adherence Counts by Facility"; 
proc sgpanel data = newcountofpoor2; 
panelby Facility / columns = 3 rows = 3; 





proc genmod data = art_gis.AdhAnalysis desc; 
class facilityid ; 
model adherence = newdistance 
    / dist=bin link = log offset =logoffset intercept = -6; 
repeated  subject = facilityid ; 












proc genmod data = art_gis.AdhAnalysis desc; 
class facilityid ; 
model adherence = newdistance agegroup newsex m newwho  
    / dist=bin link = log offset =logoffset intercept = -6; 
repeated  subject = facilityid ; 
estimate 'Poor RR Distance' newdistance 1/exp; 
estimate 'Poor RR Age Group' agegroup 1/exp; 
estimate 'Poor RR Sex' newsex 1/exp; 
estimate 'Poor RR Marital status' m 1 /exp; 




/**Adjusted ZIP - Secondary Analysis**/ 
proc nlmixed data = art_gis.AdhAnalysis method=gauss; 
  parms  
b0=0 b1=0 b2=0 b3=0 b4=0 b5=0 
        a0=0 
        sigma1=0 sigma2=0; 
  logit0 = a0 + u2  ; 
  prob0 = 1 / (1 + exp(-logit0)); 
  mu = exp(b0 + u + b1*newdistance + b2*agegroup + b3*newsex +  
      b4*m + b5*newwho + logoffset); 
  if poorcount = 0 then 
    ll = log(prob0 + (1 - prob0)*exp(-mu)); 
  else 
 ll = poorcount*log(mu) + log(1 - prob0) - mu - lgamma(poorcount + 1); 
  model poorcount ~ general(ll); 





/*Using log(# of visits as predictor)*/ 
proc genmod data = art_gis.AdhAnalysis desc; 
class facilityid ; 
model adherence = newdistance agegroup newsex m newwho logoffset  
    / dist=bin link = log intercept = -6; 
repeated  subject = facilityid ; 
estimate 'Poor RR Distance' newdistance 1/exp; 
estimate 'Poor RR Age Group' agegroup 1/exp; 
estimate 'Poor RR Sex' newsex 1/exp; 
estimate 'Poor RR Marital status' m 1 /exp; 
estimate 'Poor RR WHO' newwho 1 /exp; 










/* Removed Data for  Igawilo HC*/ 
Data art_gis.AdhSenstAnalysis; 
set art_gis.AdhAnalysis; 
if facilityid = 3 then delete; 
run; 
 
proc genmod data = art_gis.AdhSenstAnalysis desc; 
class facilityid ; 
model adherence = newdistance agegroup newsex m newwho  
    / dist=bin link = log offset =logoffset intercept = -6; 
repeated  subject = facilityid ; 
estimate 'Poor RR Distance' newdistance 1/exp; 
estimate 'Poor RR Age Group' agegroup 1/exp; 
estimate 'Poor RR Sex' newsex 1/exp; 
estimate 'Poor RR Marital status' m 1 /exp; 




/* Accounting for Within Facility Correlation*/ 
 
proc genmod data = art_gis.AdhAnalysis desc; 
class facilityid ; 
model adherence = newdistance agegroup newsex m newwho  
    / dist=bin link = log offset =logoffset intercept = -6; 
repeated  subject = facilityid / corr = cs; 
estimate 'Poor RR Distance' newdistance 1/exp; 
estimate 'Poor RR Age Group' agegroup 1/exp; 
estimate 'Poor RR Sex' newsex 1/exp; 
estimate 'Poor RR Marital status' m 1 /exp; 































proc freq data = art_gis.Adherencecombined; 
tables wardpresent * newsex / chisq; 
run; 
 
proc freq data = art_gis.Adherencecombined; 
tables wardpresent * m / chisq; 
run; 
 
proc freq data = art_gis.Adherencecombined; 
tables wardpresent * who / chisq; 
run; 
 
proc freq data = art_gis.Adherencecombined; 
tables wardpresent * adherence / chisq; 
run; 
 
